

Medical Policy:

Vpriv® (velaglucerase) intravenous infusion

POLICY NUMBER	LAST REVIEW	ORIGIN DATE
MG.MM.PH.224	January 2, 2024	2019

Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.

The treating physician or primary care provider must submit to EmblemHealth, or ConnectiCare, as applicable (hereinafter jointly referred to as “EmblemHealth”), the clinical evidence that the member meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Health care providers are expected to exercise their medical judgment in rendering appropriate care.

EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary.

If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. ConnectiCare, an EmblemHealth company, has also adopted this policy. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

Vpriv, an analogue of β-glucocerebrosidase, is indicated for long-term enzyme replacement therapy for patients with Type 1 Gaucher disease.

Length of Authorization

12 months

Dosing Limits [Medical Benefit]

Each individual dose must not exceed 60 U/kg administered intravenously no more frequently than once every 2 weeks; 72 billable units every 14 days

Guideline

INITIAL CRITERIA

- Gaucher Disease.**

- A. Patient is 4 years of age or older; **AND**
- B. Patient has Type 1 Gaucher disease; **AND**
- C. The diagnosis is established by one of the following (i or ii):
 - i. Demonstration of deficient β -glucocerebrosidase activity in leukocytes or fibroblasts; **OR**
 - ii. Molecular genetic testing documenting glucocerebrosidase gene mutation; **AND**
- D. Vpriv is prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders.

RENEWAL CRITERIA

1. Patient continues to meet criteria identified in section INITIAL CRITERIA; **AND**
2. Disease response with treatment as defined by one or more of the following (compared to pre-treatment baseline):
 - i. Improvement in symptoms (e.g., bone pain, fatigue, dyspnea, angina, abdominal distension, diminished quality of life, etc.)
 - ii. Reduction in size of liver or spleen
 - iii. Improvement in hemoglobin/anemia
 - iv. Improvement in skeletal disease (e.g., increase in lumbar spine and/or femoral neck BMD, no bone crises or bone fractures, etc.)
 - v. Improvement in platelet counts; **AND**
3. Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe hypersensitivity reactions, etc.

Applicable Procedure Codes

Code	Description
J3385	Injection, velaglucerase alfa, 100 units

Applicable NDCs

Code	Description
54092-0701-04	Vpriv 400UNIT Solution Reconstituted

ICD-10 Diagnoses

Code	Description
E75.22	Gaucher Disease

Revision History

Company(ies)	DATE	REVISION
EmblemHealth & ConnectiCare	1/2/2024	Annual Review: Updated dosing limits, added age restriction and renewal criteria
EmblemHealth & ConnectiCare	04/10/2023	Transfer from CCUM template to CoBranded medical template Retired MG.MM.PH.111

EmblemHealth & ConnectiCare	03/01/2022	Annual Revision: no criteria changes
EmblemHealth & ConnectiCare	03/17/2021	Annual Revision: Gaucher Disease: Moved the designation of "Type 1" disease from indication to the criteria.

References

1. Vpriv® intravenous infusion [prescribing information]. Lexington, MA: Shire Human Genetic Therapies; December 2020.